Palamon agrees sale of mydentist to Bridgepoint for a 3.0x return
London, UK – 21 July 2025 – Palamon Capital Partners (“Palamon”), a pan-European growth investor, today announced the sale of its majority stake in mydentist (the “Company”), the UK’s largest provider of affordable dentistry, to funds managed by Bridgepoint Advisers Limited (“Bridgepoint”). The transaction marks the conclusion of a transformative partnership with the Company’s management team, since Palamon’s acquisition of a majority stake in 2021.
mydentist operates more than 500 dental practices across the UK and supports around four million patients annually. It offers affordable dental services across three tiers: NHS dental care, myoptions private care, and Premium private care. With over 3,500 dental professionals and more than 2,500 surgeries, mydentist is the UK’s largest dental provider by revenue, practices, and clinicians.
The Company has delivered strong performance in recent years, driven by improved access to affordable care for both NHS and private patients, continued investment in digital infrastructure, and a focus on building the UK’s leading dental practice network.
The growth strategy was accelerated by the existing management team following Palamon’s acquisition of a majority stake from Carlyle in 2021. As part of a broader strategic transformation, the Company divested its non-core product distribution business, DD Group (formerly Dental Directory), refocusing mydentist as a pure-play dental services provider. The proceeds from the divestment significantly reduced leverage and provided capital to invest in infrastructure and growth.
Initiatives to strengthen dentist recruitment were also accelerated, including from overseas-qualified professionals eligible to work in the UK, broadening access to affordable treatments and improving patient outcomes across the network.
Since 2021, mydentist has delivered significant value creation through strong organic EBITDA growth, resulting in a 3.0x return for Palamon’s 2021 investors.
Fabio Massimo Giuseppetti, Partner at Palamon Capital Partners, said: “In 2021, we took the opportunity to re-invest with the mydentist leadership team in their pioneering vision to transform UK dentistry with a high-quality, affordable dental offering that delivers best-in-class care, greater choice for patients, and freedom, flexibility and support for clinicians. We are proud to have supported mydentist’s stellar management team to shape the company’s strategic direction, including the successful divestment of its subsidiary DD Group in 2022, which allowed us to accelerate investment across digitisation, estate transformation and modernisation, and operational excellence. I thank the entire mydentist team for their commitment and look forward to seeing the next phase of growth.”
Nilesh Pandya, CEO of mydentist, said: “Today marks an exciting new chapter for mydentist, for our clinicians and practice teams, and - most importantly – for our patients. We are deeply proud of the business we have built to date, and I would like to thank Palamon for their support over the last few years. Our new partnership with Bridgepoint will provide the deep market knowledge and expert resources to help us accelerate the next stage of our growth, ensuring we can provide high-quality, affordable oral care to more patients than ever before.
“We will achieve this by driving digital innovation to optimise our clinical outcomes and patient journey, investing further and faster in our state-of-the-art practice network to transform how dentistry is delivered and bring it into accessible consumer settings, and continue expanding our industry leading support team so that we can truly be the best place to work anywhere in UK dentistry.”
Tom Riall, Executive Chairman of mydentist, said: “We are delighted to welcome Bridgepoint as our new investment partner. This unlocks an exciting new future for mydentist with a significant opportunity for us to further invest in NHS dentistry and cement our position as the undisputed market champion of affordable dentistry across the UK.”
The transaction is subject to customary conditions and regulatory approvals and is expected to close in the third quarter of 2025.